Ryan D. Cassaday

6.9k citations

138 papers · 2.0k indexed · 1 hit paper · h-index 21

Impact in

Oncology top 2%
- CAR-T cell therapy research
- Viral-associated cancers and disorders
Pathology and Forensic Medicine top 2%
- Lymphoma Diagnosis and Treatment

Papers in ⓘ

Oncology 88
- CAR-T cell therapy research 62
- Viral-associated cancers and disorders 14
Hematology 36
- Chronic Myeloid Leukemia Treatments 20
- Acute Myeloid Leukemia Research 14

Co-authors: Stephen M. Hewitt (2 shared papers)Chand Khanna (2 shared papers)Lee J. Helman (2 shared papers)Richard Görlick (1 shared paper)Xiaolin Wan (1 shared paper)Choh Yeung (1 shared paper)Osarenoma Olomu (1 shared paper)Arnulfo Mendoza (1 shared paper)
Journals: Blood (41 papers)Journal of Clinical Oncology (16 papers)Biology of Blood and Marrow Transplantation (9 papers)Blood Advances (8 papers)HemaSphere (4 papers)
Partner nations: United States Germany South Africa

In The Last Decade

Ryan D. Cassaday

124 papers receiving 1.9k citations

Hit Papers

align trajectories log scale

The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis 2004 · 572 citations

Peers

Countries citing papers authored by Ryan D. Cassaday

Since Specialization

Citations

This map shows the geographic impact of Ryan D. Cassaday's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan D. Cassaday with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan D. Cassaday more than expected).

Fields of papers citing papers by Ryan D. Cassaday

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan D. Cassaday. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan D. Cassaday. The network helps show where Ryan D. Cassaday may publish in the future.

Co-authors

The 25 scholars most cited alongside Ryan D. Cassaday, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ryan D. Cassaday Line = papers co-authored together Ryan D. Cassaday links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 138 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis Nature Medicine ·Chand Khanna, Xiaolin Wan, Seuli Bose, Ryan D. Cassaday, Osarenoma Olomu, Arnulfo Mendoza, Choh Yeung, Richard Görlick, Stephen M. Hewitt, Lee J. Helman Hit paper breakdown →	2004	572
2	Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study The Lancet Haematology ·Hagop M. Kantarjian, Daniel J. DeAngelo, Anjali S. Advani, Matthias Stelljes, Partow Kebriaei, Ryan D. Cassaday, Akil Merchant, Naohito Fujishima, Toshiki Uchida, María Calbacho, Anna Ejduk, Susan O’Brien, Elias Jabbour, Hui Zhang, Barbara Sleight, Erik Vandendries, David I. Marks	2017	138
3	Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy British Journal of Haematology ·Stephen D. Smith, Brian G. Till, Mazyar Shadman, Ryan C. Lynch, Andrew J. Cowan, Qian Wu, Jenna Voutsinas, Heather A. Rasmussen, Katherine Blue, Chaitra S. Ujjani, Andrei R. Shustov, Ryan D. Cassaday, Jonathan R. Fromm, Ajay K. Gopal	2020	69
4	Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy Blood Advances ·Mazyar Shadman, Jordan Gauthier, Kevin A. Hay, Jenna Voutsinas, Filippo Milano, Ang Li, Alexandre V. Hirayama, Mohamed L. Sorror, Sindhu Cherian, Xueyan Chen, Ryan D. Cassaday, Brian G. Till, Ajay K. Gopal, Brenda M. Sandmaier, David G. Maloney, Cameron J. Turtle	2019	67
5	A Phase I Study of Immunization Using Particle-Mediated Epidermal Delivery of Genes for gp100 and GM-CSF into Uninvolved Skin of Melanoma Patients Clinical Cancer Research ·Ryan D. Cassaday, Paul M. Sondel, David M. King, Michael D. Macklin, Jacek Gan, T F Warner, Cindy Zuleger, Alan J. Bridges, Heidi Schalch, Kyung Mann Kim, Jacquelyn A. Hank, David M. Mahvi, Mark R. Albertini	2007	59
6	Impact of oncogene rearrangement patterns on outcomes in patients with double‐hit non‐Hodgkin lymphoma Cancer ·Daniel J. Landsburg, Adam M. Petrich, Jeremy S. Abramson, Aliyah R. Sohani, Oliver W. Press, Ryan D. Cassaday, Julio C. Chávez, Kevin Song, Andrew D. Zelenetz, Mitul Gandhi, Namrata Shah, Timothy S. Fenske, Jesse Jaso, L. Jeffrey Medeiros, David T. Yang, Chadi Nabhan	2015	58
7	A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma Clinical Lymphoma Myeloma & Leukemia ·Ryan D. Cassaday, André Goy, Suresh H. Advani, Purvi Chawla, Rajesh Nachankar, Mansi Gandhi, Ajay K. Gopal	2015	54
8	A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. PubMed ·Chand Khanna, Jennifer Prehn, David W. Hayden, Ryan D. Cassaday, Jana Caylor, Shevin T. Jacob, Seuli Bose, Sung Hyeok Hong, Stephen M. Hewitt, Lee J. Helman	2002	48
9	Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia Biology of Blood and Marrow Transplantation ·David I. Marks, Partow Kebriaei, Matthias Stelljes, Nicola Gökbuget, Hagop M. Kantarjian, Anjali S. Advani, Akil Merchant, Wendy Stock, Ryan D. Cassaday, Tao Wang, Hui Zhang, Fausto R. Loberiza, Erik Vandendries, Daniel J. DeAngelo	2019	46
10	Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia Cancer ·Wendy Stock, Giovanni Martinelli, Matthias Stelljes, Daniel J. DeAngelo, Nicola Gökbuget, Anjali S. Advani, Susan O’Brien, Michaela Liedtke, Akil Merchant, Ryan D. Cassaday, Tao Wang, Hui Zhang, Erik Vandendries, Elias Jabbour, David I. Marks, Hagop M. Kantarjian	2020	43
11	Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study The Lancet Haematology ·Ryan C. Lynch, Ryan D. Cassaday, Stephen D. Smith, Jonathan R. Fromm, Andrew J. Cowan, Edus H. Warren, Mazyar Shadman, Andrei R. Shustov, Brian G. Till, Chaitra S. Ujjani, Edward N. Libby, Mary Philip, Hilary Coye, Christen N. Martino, Sandra L Bhark, Karolyn Morris, Heather Rasmussen, Fatemeh Behnia, Jenna Voutsinas, Ajay K. Gopal	2021	33
12	Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission Biology of Blood and Marrow Transplantation ·Andrew J. Cowan, Philip A. Stevenson, Ryan D. Cassaday, Solomon A. Graf, Jonathan R. Fromm, David Wu, Leona Holmberg, Brian G. Till, Thomas R. Chauncey, Stephen D. Smith, Mary Philip, Johnnie J. Orozco, Andrei R. Shustov, Damian J. Green, Edward N. Libby, William Bensinger, Mazyar Shadman, David G. Maloney, Oliver W. Press, Ajay K. Gopal	2015	32
13	Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy PubMed ·Krishna R. Juluri, Chloe Siu, Ryan D. Cassaday	2022	31
14	Safety and Activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Initial Results of a Phase I/II Trial Blood ·Ryan D. Cassaday, Jonathan R. Fromm, Andrew J. Cowan, Edward N. Libby, Mary Philip, Fatemeh Behnia, Margaret E. Nartea, Oliver W. Press, Ajay K. Gopal	2016	31
15	Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Blood ·Alexandre V. Hirayama, Jordan Gauthier, Kevin A. Hay, Alyssa Sheih, Sindhu Cherian, Xueyan Chen, Barbara S. Pender, Reed M. Hawkins, Aesha Vakil, Rachel N. Steinmetz, Tinh-Doan Phi, Aude G. Chapuis, Brian G. Till, Hans‐Peter Kiem, Mazyar Shadman, Ryan D. Cassaday, Utkarsh Acharya, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle	2018	30
16	Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22 Clinical Cancer Research ·Hagop M. Kantarjian, Wendy Stock, Ryan D. Cassaday, Daniel J. DeAngelo, Elias Jabbour, Susan O’Brien, Matthias Stelljes, Tao Wang, M. Luisa Paccagnella, Kevin T. Nguyen, Barbara Sleight, Erik Vandendries, Alexander Neuhof, Alexander Laird, Anjali S. Advani	2021	29
17	End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology ·Bijal Shah, Michael Bishop, Olalekan O. Oluwole, Aaron C. Logan, Maria R. Baer, William B. Donnellan, Kristen Marie Carr-O'Dwyer, Houston Holmes, Martha Arellano, Armin Ghobadi, John M. Pagel, Yi Lin, Ryan D. Cassaday, Jae Hong Park, Armen Mardiros, Tong Shen, Lovely Goyal, Remus Vezan, Rajul K. Jain, William G. Wierda	2019	29
18	How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia Blood ·Noam E. Kopmar, Ryan D. Cassaday	2022	24
19	Myeloablative I-131-Tositumomab with Escalating Doses of Fludarabine and Autologous Hematopoietic Transplantation for Adults Age ≥ 60 Years with B Cell Lymphoma Biology of Blood and Marrow Transplantation ·Ajay K. Gopal, Ted Gooley, Joseph G. Rajendran, John M. Pagel, Darrell R. Fisher, David G. Maloney, Frederick R. Appelbaum, Ryan D. Cassaday, Andrew Shields, Oliver W. Press	2014	21
20	Regression of Hodgkin Lymphoma After Discontinuation of a Tumor Necrosis Factor Inhibitor for Crohn's Disease: A Case Report and Review of the Literature Clinical Lymphoma Myeloma & Leukemia ·Ryan D. Cassaday, Jeffrey Malik, Julie Chang	2011	20

About Ryan D. Cassaday

Ryan D. Cassaday is a scholar working on Oncology, Hematology, Pathology and Forensic Medicine, Genetics and Public Health, Environmental and Occupational Health, having authored 138 papers that have together received 2.0k indexed citations. Recurring topics across this work include CAR-T cell therapy research (62 papers), Lymphoma Diagnosis and Treatment (57 papers), Acute Lymphoblastic Leukemia research (50 papers), Chronic Lymphocytic Leukemia Research (23 papers), Chronic Myeloid Leukemia Treatments (20 papers), Acute Myeloid Leukemia Research (14 papers), Viral-associated cancers and disorders (14 papers) and CNS Lymphoma Diagnosis and Treatment (9 papers). The work is most often cited by research in Oncology (1.0k citations), Pathology and Forensic Medicine (580 citations), Hematology (354 citations), Neurology (308 citations) and Genetics (214 citations). Ryan D. Cassaday has collaborated with scholars based in United States, Germany and South Africa. Frequent co-authors include Stephen M. Hewitt, Chand Khanna, Lee J. Helman, Richard Görlick, Xiaolin Wan, Choh Yeung, Osarenoma Olomu, Arnulfo Mendoza, Ajay K. Gopal and Brian G. Till. Their work appears in journals such as Blood, Journal of Clinical Oncology, Biology of Blood and Marrow Transplantation, Blood Advances and HemaSphere.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact